[14C]Pirtobrutinib | Interleukin Related interleukin-related.com

Product Name :
[14C]Pirtobrutinib

Search keywords :
Pirtobrutinib

drugId :
null

Target Vo:
Tyrosine-protein kinase BTK

Target Vo Short Name :
BTK

Moa_Name:
Tyrosine-protein kinase BTK inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Redx Pharma Ltd

Active Company_Name :
Eli Lilly And Company

Active Indication_Name:

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
NR1D1 Antibody (YA1426) supplier
NLRP3 Rabbit pAb site
Calumenin Antibody (YA813): Calumenin Antibody (YA813) is a non-conjugated and Mouse origined monoclonal antibody about 37 kDa, targeting to Calumenin (4C6). It can be used for WB assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts